Torrent Pharmaceuticals has released its audited financial results for the quarter and year ended March 31, 2026. The company reported a 12% increase in consolidated net profit to ₹2,138 crore for the full fiscal year FY26, compared to ₹1,911 crore in the previous year. Total revenues for the year grew by 21% to ₹13,980 crore, up from ₹11,516 crore in FY25. This growth was driven by robust performance across key geographies, including India, the United States, and Brazil, alongside the initial integration of J.B. Chemicals & Pharmaceuticals (JB Pharma).

Q4 FY26 Highlights

In the fourth quarter of FY26, the company recorded total revenues of ₹4,197 crore, compared to ₹2,959 crore in the corresponding period of the previous year. Consolidated net profit for the quarter stood at ₹390 crore, against ₹498 crore in the year-ago period. This decline was attributed to exceptional items and acquisition-related costs associated with the JB Pharma integration. Excluding JB Pharma, the base business recorded revenue growth of 16% for the quarter.

Q4 FY26 Key Metrics

The following table summarises the key financial metrics for Q4 FY26 on a year-on-year basis:

Q4 FY26 Segment Revenue

The India segment led the growth with a 43% surge during the quarter. The following table presents the segment-wise revenue breakdown for Q4 FY26:

FY26 Revenue Summary

The company's revenue performance for the full fiscal year reflected strong growth across all major markets. The India segment contributed ₹7,645 crore, growing by 20%, while the United States and Brazil segments grew by 24% each to ₹1,363 crore and ₹1,362 crore respectively.

Dividend and Fundraising

The Board has recommended a final dividend of ₹9 per equity share for the fiscal year 2025-26, with Friday, May 29, 2026, fixed as the record date. An interim dividend of ₹29 per share was previously paid during the last quarter. Additionally, the Board has recommended enabling approval for the issuance of equity shares, including convertible bonds or debentures, through Qualified Institutional Placement (QIP) or other modes for an amount not exceeding ₹5,000 crores.

Conference Call Transcript

Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the transcript of the conference call with analysts and investors on the audited financial results for the quarter and year ended March 31, 2026, has been placed on the company's website.

Torrent Pharmaceuticals has shared detailed operational guidance across its key markets while two prominent brokerages — Morgan Stanley and Jefferies — maintain their respective ratings on the stock, both anchored by the company's robust India business performance and ongoing JB Pharma integration.

Market-Wise Growth Outlook

Torrent Pharma has provided a differentiated growth outlook across its international markets. The company projects low single-digit growth of below 5% for its German business in the coming year, while the U.S. business is expected to grow in single digits. Brazil, however, stands out with anticipated double-digit growth of 10% to 15% for the next year.

On the India front, the company expects strong growth fuelled by the semaglutide launch, continued strength in the Curatio and chronic businesses, and new first-to-market product introductions. The company anticipates a better year for organic growth compared to the previous year, provided there are no geopolitical demand shocks.

Semaglutide and India Field Force Expansion

A key growth driver for Torrent Pharma in India is the semaglutide launch, which the company estimates will generate sales of INR 200–250 crore in the first year. This represents a significantly larger opportunity compared to past launches such as sitagliptin, which reached INR 70–75 crore. The company also holds a 38% market share in semaglutide, with FY27 sales guidance in the range of ₹2–2.5bn.

To support its India growth strategy, Torrent Pharma plans to expand its India field force to 7,500 members by FY '27, following the full merger of JB Pharma's medical representative strength, with no further headcount growth anticipated beyond that point.

R&D Spending Plans

On the research and development front, Torrent Pharma has guided for R&D spending of around 5% of revenues for FY '26, with a planned increase of 0.5%, directed primarily towards India and the U.S. markets.

JB Pharma Integration and Cost Synergies

Torrent Pharma has confirmed continued progress on cost synergies from the JB Pharma deal, projecting total synergies of INR 450 crore by year three. The phasing of these savings is structured as approximately 20% in year one, 60% to 80% cumulative by year two, and the remaining 20% in year three. Notably, margin growth for the merged entity has exceeded expectations, as certain costs were reduced earlier than originally planned. Morgan Stanley has estimated JB Pharma merger synergies at ₹4–4.5bn, consistent with the company's own guidance trajectory.

Brokerage Views

Morgan Stanley has maintained an Equal Weight rating on Torrent Pharmaceuticals with a target price of ₹4580, citing Q4 EBITDA performance in line with expectations and India business growth of 15%. Jefferies has maintained a Buy rating with a target price of ₹5350, highlighting steady India growth of 15% YoY and core performance excluding JB Pharma consolidation as in line with expectations.

Both brokerages have underscored Torrent Pharmaceuticals' steady India business momentum, with 15% growth serving as a common data point across both assessments. The progress on JB Pharma merger synergies, the early traction of semaglutide, and the company's differentiated international market strategy remain focal areas for investors tracking the company's performance.